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Letters to the Editor
Improving Quality
of Life and Functional
Capacity in Atrial Fibrillation
and Congestive Heart Failure
We read with interest the paper by Suman-Horduna et al. (1)
published in the January 2013 issue of the Journal. The investiga-
tors analyzed important quality-of-life data from a substantial
substudy (n  749) of a landmark trial (2), comparing rate control
to rhythm control for patients with paroxysmal (30%) or persis-
tent atrial fibrillation (AF) and congestive heart failure (CHF).Overall, each strategy was associated with similar improvements in
symptoms and quality of life, but results were confounded by the
high proportion of patients with paroxysmal AF (29.6%) assigned
to rate control who remained in sinus rhythm (i.e., crossed over to
rhythm control) and by patients assigned to rhythm control who
remained in AF (22.4%) (i.e., in whom rhythm control failed).
We previously conducted a small, randomized study exclusively
of patients with persistent AF and CHF (3), and encountered
similar problems in maintaining sinus rhythm but with no spon-
taneous return to sinus rhythm in those assigned to rate control;
therefore, we had a much lower rate of cross over than in the
AF-CHF trial. We found significant improvements in quality of
life, left ventricular function, and N-terminal pro–brain natriuretic
peptide concentrations overall, which benefited those in whom
sinus rhythm was restored and maintained during follow-up. The
6-min walk test distance also improved for patients in whom a
rhythm control strategy was successful.
Unfortunately, despite some encouraging results, the Achilles’
heel of a rhythm control strategy remains arrhythmia recurrence.
Treatment directed at CHF, including angiotensin-converting
enzyme inhibitors, beta-blockers, and aldosterone antagonists,
helps to reduce the incidence of AF (4). However, safe and
effective antiarrhythmic therapy is lacking for patients with left
ventricular dysfunction. This includes amiodarone, which was
associated with excess mortality in the SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial) study among patients with
more advanced symptoms (5). Although preliminary results of
catheter ablation, either of AF itself or of atrioventricular nodal
ablation followed by biventricular pacing (6), are encouraging,
adequately powered randomized clinical trials are needed to
evaluate longer term safety and efficacy before any firm recommen-
dations can be made. However, in the context of CHF, the
evidence that it is better to be in sinus rhythm rather than AF is
compelling. We just need to identify interventions that are less
harmful or toxic than the problem.
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Reply
We thank Drs. Shelton and Cleland for their interest in our
study (1) and for their thoughtful comments. We agree with
their general statements regarding limitations of antiarrhythmic
agents and the need to develop and rigorously test more
effective rhythm control strategies. However, a few subtle
inaccuracies merit clarification. First, recurrence of atrial fibril-
lation in patients randomized to rhythm control is not synon-
ymous with crossover, as implied. Recurrences (and adverse
effects) are intrinsic to any rhythm control strategy, including
approaches centered on catheter ablation. Rather, in random-
ized trials, crossover refers to a deliberate investigator-approved
change in treatment arm. Second, although large-scale cross-
over in randomized trials remains a vexing problem, its primary
impact on intention-to-treat analyses is to decrease statistical
power. The suggestion that unidirectional crossover (i.e., from
rhythm to rate control but not vice versa) produces less biased
estimates than bidirectional crossover is fallacious. Under certain
conditions, the reverse may be true. Third, insinuating that the
CAFÉ-II (Chronic Atrial Fibrillation and Heart Failure) trial (2),
owever, important, was subject to less confounding than the
F-CHF (Atrial Fibrillation and Congestive Heart Failure) trial
3) is unfounded, if only by virtue of the much larger (N  1,376
s. 61) sample’s enhanced ability to balance unknown or unmea-
ured influential factors, produce normal sample distributions,
ield more precise standard errors, and provide greater statistical
ower.
We share Drs. Shelton and Cleland’s interest in determining
hether more effective and/or less toxic rhythm control strategies
ay outperform rate control. Importantly, this is not analogous to
esting the hypothesis that sinus rhythm is superior to atrial
brillation. Claiming that the statements are equivalent assumes
hat rhythm control is 100% effective, carries no risks or costs, and
as no salutary or harmful effects beyond maintaining sinus
hythm, and that rate control is indistinguishable from no therapy
t all. A few studies support the potential for better rhythm control
trategies to improve outcomes in patients with heart failure
ompared with rate control (4), particularly for “softer” endpoints
1,2) and in selected patient subgroups (5). However, extensive
n-treatment and underlying rhythm analyses from the AF-CHF
rial found no differences in survival and cardiovascular outcomes
hether efficacy was analyzed by initially assigned or time-dependent
odeling of rhythm versus rate control strategies (6). Moreover, to
solate the effect of underlying rhythm irrespective of treatment
trategy, presence of atrial fibrillation, and sinus rhythm were
odeled in a time-dependent fashion. Outcomes were not im-
roved by maintaining sinus rhythm. As such, we challenge the
ssertion that compelling evidence supports the notion that less
armful or toxic rhythm control should outperform rate control.
he issue remains unresolved. Because overwhelming evidence
urrently indicates that rhythm control is not systematically supe-
ior to rate control in patients with atrial fibrillation and symp-
omatic heart failure, the burden of proof will be on future
trategies to demonstrate that this reality has changed.rina Suman-Horduna, MD, MSc
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ario Talajic, MD
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Niacin Therapy Lives
for Another Day—Maybe?
Being enthusiastic regarding the importance of high-density lipo-
protein cholesterol (HDL-C) and the potential for HDL-C–
raising therapies (1–3), we were disappointed in the outcomes of
the early cholesterol ester transport protein inhibition trial with
torcetrapib (4) as well as the recent AIM-HIGH (Atherothrom-
bosis Intervention in Metabolic Syndrome with Low HDL/High
Triglycerides: Impact on Global Health Outcomes) trial (5) with
extended-release (ER) niacin. Although AIM-HIGH was the
largest and most publicized niacin trial in decades, disappointing
results may partly be due to limitations in the trial, including
higher doses of simvastatin and greater use of ezetimibe (22% vs.
10%) in the statin-only compared with the statin/niacin arm, as
well as the fact that the statin-only group actually received up to
200 mg of immediate-release niacin, and did have an increase in
HDL-C (9.8%) and a reduction in triglycerides (TGs) (8.1%)
and low-density lipoprotein cholesterol (LDL-C) (5.5%) at 2
years. Also, the trial was stopped after only 36 months, which may
have been too short term to notice benefits in patients with
baseline LDL-C levels of only 71 mg/dl, realizing that the original
Lipid Research Clinic–Coronary Prevention Trial with cholesty-
ramine (6) and the 4S (Scandinavian Simvastatin Survival Study)
with simvastatin (7) included patients with markedly higher levels
